Baets, J., De Jonghe, P. & Timmerman, V. Recent advances in Charcot–Marie–Tooth disease. Curr. Opin. Neurol. 27, 532–540 (2014).
Pisciotta, C. & Shy, M. E. Neuropathy. Handb. Clin. Neurol 148, 653–665 (2018).
Saporta, M. A. & Shy, M. E. Inherited peripheral neuropathies. Neurol. Clin. 31, 597–619 (2013).
Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11–21 (2018).
Benson, M. D. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 22–31 (2018).
Passage, E. et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat. Med. 10, 396–401 (2004).
Lewis, R. A. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A. JAMA Neurol. 70, 981–987 (2013).
Pareyson, D. et al. Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 10, 320–328 (2011).
Verhamme, C. et al. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med. 7, 70 (2009).
Burns, J. et al. Ascorbic acid for Charcot–Marie–Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol. 8, 537–544 (2009).
Garofalo, K. et al. Oral l-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J. Clin. Investig. 121, 4735–4745 (2011).
Fridman, V. et al. Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology 92, 359 (2019).
Colman, A. Profile of John Gurdon and Shinya Yamanaka, 2012 Nobel Laureates in medicine or physiology. Proc. Natl Acad. Sci. USA 110, 5740–5741 (2013).
Lee, G. et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461, 402–406 (2009).
Saporta, M. A. et al. Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties. Exp. Neurol. 263, 190–199 (2015).
Harschnitz, O. et al. Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model. Ann. Neurol. 80, 71–88 (2016).
Perez-Siles, G. et al. Energy metabolism and mitochondrial defects in X-linked Charcot-Marie-Tooth (CMTX6) iPSC-derived motor neurons with the p.R158H PDK3 mutation. Sci. Rep. 10, 9262 (2020).
Cutrupi, A. N. et al. Novel gene–intergenic fusion involving ubiquitin E3 ligase UBE3C causes distal hereditary motor neuropathy. Brain 146, 880–897 (2023).
Maury, Y. et al. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat. Biotechnol. 33, 89–96 (2015).
Guo, W. et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 8, 861 (2017).
Van Lent, J. et al. Induced pluripotent stem cell-derived motor neurons of CMT type 2 patients reveal progressive mitochondrial dysfunction. Brain 144, 2471–2485 (2021).
Faye, P.-A. et al. Optimized protocol to generate spinal motor neuron cells from induced pluripotent stem cells from Charcot Marie Tooth patients. Brain Sci. 10, 407 (2020).
LaVaute, T. M. et al. Regulation of neural specification from human embryonic. Stem Cells BMP Fgf. Stem Cells 27, 1741–1749 (2009).
Miressi, F. et al. GDAP1 involvement in mitochondrial function and oxidative stress, investigated in a Charcot-Marie-Tooth model of hiPSCs-derived motor neurons. Biomedicines 9, 945 (2021).
Feliciano, C. M. et al. Allele-specific gene editing rescues pathology in a human model of Charcot-Marie-Tooth disease type 2E. Front Cell Dev. Biol. 9, 723023 (2021).
Limone, F. et al. Efficient generation of lower induced motor neurons by coupling Ngn2 expression with developmental cues. Cell Rep. 42, 111896 (2023).
Perez-Siles, G. et al. Modelling the pathogenesis of X-linked distal hereditary motor neuropathy using patient-derived iPSCs. Dis. Model Mech. 13, dmm041541 (2020).
Clark, A. J. et al. An iPSC model of hereditary sensory neuropathy-1 reveals L-serine-responsive deficits in neuronal ganglioside composition and axoglial interactions. Cell Rep. Med. 2, 100345 (2021).
Romano, R. et al. Alteration of the late endocytic pathway in Charcot–Marie–Tooth type 2B disease. Cell. Mol. Life Sci. 78, 351–372 (2021).
Chambers, S. M. et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat. Biotechnol. 30, 715–720 (2012).
Schrenk-Siemens, K. et al. PIEZO2 is required for mechanotransduction in human stem cell–derived touch receptors. Nat. Neurosci. 18, 10–16 (2015).
Middleton, S. J. et al. Studying human nociceptors: from fundamentals to clinic. Brain 144, 1312–1335 (2021).
Nickolls, A. R. et al. Transcriptional programming of human mechanosensory neuron subtypes from pluripotent stem cells. Cell Rep. 30, 932–946 (2020).
Alshawaf, A. J. et al. Phenotypic and functional characterization of peripheral sensory neurons derived from human embryonic stem cells. Sci. Rep. 8, 603 (2018).
Saito-Diaz, K., Street, J. R., Ulrichs, H. & Zeltner, N. Derivation of peripheral nociceptive, mechanoreceptive, and proprioceptive sensory neurons from the same culture of human pluripotent stem cells. Stem Cell Rep. 16, 446–457 (2021).
Ernsberger, U. Role of neurotrophin signalling in the differentiation of neurons from dorsal root ganglia and sympathetic ganglia. Cell Tissue Res. 336, 349–384 (2009).
Zeidler, M. et al. NOCICEPTRA: gene and microRNA signatures and their trajectories characterizing human iPSC‐derived nociceptor maturation. Adv. Sci. 8, 2102354 (2021).
Eberhardt, E. et al. Pattern of functional TTX-resistant sodium channels reveals a developmental stage of human iPSC- and ESC-derived nociceptors. Stem Cell Rep. 5, 305–313 (2015).
Deng, T. et al. Scalable generation of sensory neurons from human pluripotent stem cells. Stem Cell Rep. 18, 1030–1047 (2023).
Oh, Y. et al. Functional coupling with cardiac muscle promotes maturation of hPSC-derived sympathetic neurons. Cell Stem Cell 19, 95–106 (2016).
Kirino, K., Nakahata, T., Taguchi, T. & Saito, M. K. Efficient derivation of sympathetic neurons from human pluripotent stem cells with a defined condition. Sci. Rep. 8, 12865 (2018).
Frith, T. J. et al. Human axial progenitors generate trunk neural crest cells in vitro. Elife 7, e35786 (2018).
Wu, H.-F. et al. Norepinephrine transporter defects lead to sympathetic hyperactivity in Familial Dysautonomia models. Nat. Commun. 13, 7032 (2022).
Wu, H.-F. et al. Parasympathetic neurons derived from human pluripotent stem cells model human diseases and development. Cell Stem Cell. S1934–5909, 00092–4. https://pubmed.ncbi.nlm.nih.gov/38608707/ (2024) Online ahead of print.
Muhammad, A. et al. Cell transplantation strategies for acquired and inherited disorders of peripheral myelin. Ann. Clin. Transl. Neurol. 5, 186–200 (2018).
Huang, Z., Powell, R., Kankowski, S., Phillips, J. B. & Haastert-Talini, K. Culture conditions for human induced pluripotent stem cell-derived Schwann cells: a two-centre study. Int. J. Mol. Sci. 24, 5366 (2023).
Majd, H. et al. Deriving Schwann cells from hPSCs enables disease modeling and drug discovery for diabetic peripheral neuropathy. Cell Stem Cell 30, 632–647 (2023).
Kim, H.-S., Kim, J. Y., Song, C. L., Jeong, J. E. & Cho, Y. S. Directly induced human Schwann cell precursors as a valuable source of Schwann cells. Stem Cell Res. Ther. 11, 257 (2020).
Kim, H.-S. et al. Schwann cell precursors from human pluripotent stem cells as a potential therapeutic target for Myelin repair. Stem Cell Rep. 8, 1714–1726 (2017).
Mukherjee-Clavin, B. et al. Comparison of three congruent patient-specific cell types for the modelling of a human genetic Schwann-cell disorder. Nat. Biomed. Eng. 3, 571–582 (2019).
Prior, R. et al. Defective Schwann cell lipid metabolism alters plasma membrane dynamics in Charcot-Marie-Tooth disease 1A. Preprint at bioRxiv https://doi.org/10.1101/2023.04.02.535224 (2023).
Adameyko, I. et al. Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. Cell 139, 366–379 (2009).
Paratore, C., Goerich, D. E., Suter, U., Wegner, M. & Sommer, L. Survival and glial fate acquisition of neural crest cells are regulated by an interplay between the transcription factor Sox10 and extrinsic combinatorial signaling. Development 128, 3949–3961 (2001).
Britsch, S. et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev. 15, 66–78 (2001).
Dyachuk, V. et al. Parasympathetic neurons originate from nerve-associated peripheral glial progenitors. Science 345, 82–87 (2014).
Kastriti, M. E. et al. Schwann cell precursors represent a neural crest‐like state with biased multipotency. EMBO J. 41, 108780 (2022).
Xie, M. et al. Schwann cell precursors contribute to skeletal formation during embryonic development in mice and zebrafish. Proc. Natl Acad. Sci. USA 116, 15068–15073 (2019).
Jessen, K. R. & Mirsky, R. Schwann cell precursors; multipotent glial cells in embryonic nerves. Front. Mol. Neurosci. 12, 69 (2019).
Jessen, K. R. & Mirsky, R. The origin and development of glial cells in peripheral nerves. Nat. Rev. Neurosci. 6, 671–682 (2005).
Stassart, R. M. & Woodhoo, A. Axo‐glial interaction in the injured PNS. Dev. Neurobiol. 81, 490–506 (2021).
Nitzan, E., Pfaltzgraff, E. R., Labosky, P. A. & Kalcheim, C. Neural crest and Schwann cell progenitor-derived melanocytes are two spatially segregated populations similarly regulated by Foxd3. Proc. Natl Acad. Sci. USA 110, 12709–12714 (2013).
Van Raamsdonk, C. D. & Deo, M. Links between Schwann cells and melanocytes in development and disease. Pigment Cell Melanoma Res. 26, 634–645 (2013).
Colombo, S. et al. Stabilization of β-catenin promotes melanocyte specification at the expense of the Schwann cell lineage. Development 149, dev194407 (2022).
Marathe, H. G. et al. BRG1 interacts with SOX10 to establish the melanocyte lineage and to promote differentiation. Nucleic Acids Res. 45, 6442–6458 (2017).
Slutsky, S. G., Kamaraju, A. K., Levy, A. M., Chebath, J. & Revel, M. Activation of Myelin genes during transdifferentiation from melanoma to glial cell phenotype. J. Biol. Chem. 278, 8960–8968 (2003).
Rambow, F. et al. New functional signatures for understanding melanoma biology from tumor cell lineage-specific analysis. Cell Rep. 13, 840–853 (2015).
Smith, A. et al. HDAC6 inhibition corrects electrophysiological and axonal transport deficits in a human stem cell‐based model of Charcot‐Marie‐Tooth disease (type 2D). Adv. Biol. 6, 2101308 (2022).
Kennerson, M. L. et al. Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy. Am. J. Hum. Genet. 86, 343–352 (2010).
Zhu, Y. et al. Sorbitol reduction via govorestat ameliorates synaptic dysfunction and neurodegeneration in sorbitol dehydrogenase deficiency. JCI Insight 8, e164954 (2023).
McDermott, L. A. et al. Defining the functional role of NaV1.7 in human nociception. Neuron 101, 905–919 (2019).
Haidar, M. et al. Neuropathy-causing mutations in HSPB1 impair autophagy by disturbing the formation of SQSTM1/p62 bodies. Autophagy 15, 1051–1068 (2019).
Alderson, T. R. et al. A weakened interface in the P182L variant of HSP27 associated with severe Charcot-Marie-Tooth neuropathy causes aberrant binding to interacting proteins. EMBO J. 40, 103811 (2021).
Maciel, R., Correa, R., Bosso Taniguchi, J., Prufer Araujo, I. & Saporta, M. A. Human tridimensional neuronal cultures for phenotypic drug screening in inherited peripheral neuropathies. Clin. Pharm. Ther. 107, 1231–1239 (2020).
Kenvin, S. et al. Threshold of heteroplasmic truncating MT-ATP6 mutation in reprogramming, Notch hyperactivation and motor neuron metabolism. Hum. Mol. Genet. 31, 958–974 (2022).
Carrió, M. et al. Reprogramming captures the genetic and tumorigenic properties of neurofibromatosis type 1 plexiform neurofibromas. Stem Cell Rep. 12, 411–426 (2019).
Cutrupi, A. N., Brewer, M. H., Nicholson, G. A. & Kennerson, M. L. Structural variations causing inherited peripheral neuropathies: a paradigm for understanding genomic organization, chromatin interactions, and gene dysregulation. Mol. Genet. Genom. Med. 6, 422–433 (2018).
Sudmant, P. H. et al. An integrated map of structural variation in 2,504 human genomes. Nature 526, 75–81 (2015).
Drew, A. P., Cutrupi, A. N., Brewer, M. H., Nicholson, G. A. & Kennerson, M. L. A 1.35 Mb DNA fragment is inserted into the DHMN1 locus on chromosome 7q34–q36.2. Hum. Genet. 135, 1269–1278 (2016).
Brewer, M. H. et al. Whole genome sequencing identifies a 78 kb insertion from chromosome 8 as the cause of Charcot-Marie-Tooth neuropathy CMTX3. PLoS Genet. 12, 1006177 (2016).
D’ydewalle, C. et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat. Med. 17, 968–974 (2011).
Kalmar, B. et al. Mitochondrial deficits and abnormal mitochondrial retrograde axonal transport play a role in the pathogenesis of mutant Hsp27-induced Charcot Marie Tooth disease. Hum. Mol. Genet. 26, 3313–3326 (2017).
Baloh, R. H., Schmidt, R. E., Pestronk, A. & Milbrandt, J. Altered Axonal Mitochondrial Transport In The Pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J. Neurosci. 27, 422–430 (2007).
Alecu, I. et al. Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction. J. Lipid Res. 58, 42–59 (2017).
Adriaenssens, E. et al. Small heat shock proteins operate as molecular chaperones in the mitochondrial intermembrane space. Nat. Cell Biol. 25, 467–480 (2023).
Hagemann, C. et al. Axonal length determines distinct homeostatic phenotypes in human iPSC derived motor neurons on a bioengineered platform. Adv. Health. Mater. 11, 2101817 (2022).
Butler, L. et al. HDAC6 inhibition partially alleviates mitochondrial trafficking defects and restores motor function in human motor neuron and zebrafish models of Charcot-Marie-Tooth disease type 2 A. Preprint at bioRxiv https://doi.org/10.1101/2022.07.05.498819 (2022).
Pal, A. et al. High content organelle trafficking enables disease state profiling as powerful tool for disease modelling. Sci. Data 5, 180241 (2018).
Nijssen, J., Aguila, J., Hoogstraaten, R., Kee, N. & Hedlund, E. Axon-Seq decodes the motor axon transcriptome and its modulation in response to ALS. Stem Cell Rep. 11, 1565–1578 (2018).
Badiola-Mateos, M., Osaki, T., Kamm, R. D. & Samitier, J. In vitro modelling of human proprioceptive sensory neurons in the neuromuscular system. Sci. Rep. 12, 21318 (2022).
Monje, P. V., Sant, D. & Wang, G. Phenotypic and functional characteristics of human Schwann cells as revealed by cell-based assays and RNA-SEQ. Mol. Neurobiol. 55, 6637–6660 (2018).
Clark, A. J. et al. Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination. Brain 140, 898–913 (2017).
Sharma, A. D. et al. Engineering a 3D functional human peripheral nerve in vitro using the Nerve-on-a-Chip platform. Sci. Rep. 9, 8921 (2019).
Louit, A., Beaudet, M.-J., Pépin, R. & Berthod, F. Differentiation of human induced pluripotent stem cells into mature and myelinating Schwann cells. Tissue Eng. Part C. Methods 29, 134–143 (2023).
Sabblah, T. T. et al. A novel mouse model carrying a human cytoplasmic dynein mutation shows motor behavior deficits consistent with Charcot-Marie-Tooth type 2 O disease. Sci. Rep. 8, 1739 (2018).
Ang, E.-T. et al. Motor axonal sprouting and neuromuscular junction loss in an animal model of Charcot-Marie-Tooth disease. J. Neuropathol. Exp. Neurol. 69, 281–293 (2010).
Sleigh, J. N., Grice, S. J., Burgess, R. W., Talbot, K. & Cader, M. Z. Neuromuscular junction maturation defects precede impaired lower motor neuron connectivity in Charcot-Marie-Tooth type 2D mice. Hum. Mol. Genet. 23, 2639–2650 (2014).
Jones, R. A. et al. Cellular and molecular anatomy of the human neuromuscular junction. Cell Rep. 21, 2348–2356 (2017).
Stoklund Dittlau, K. et al. Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition. Stem Cell Rep. 16, 2213–2227 (2021).
Stoklund Dittlau, K. et al. FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms. Mol. Neurodegener. 18, 5 (2023).
Rose, N. et al. Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities. Acta Neuropathol. 144, 1005–1025 (2022).
Sleigh, J. N. et al. Boosting peripheral BDNF rescues impaired in vivo axonal transport in CMT2D mice. JCI Insight 8, e157191 (2023).
Amin, N. D. & Paşca, S. P. Building models of brain disorders with three-dimensional organoids. Neuron 100, 389–405 (2018).
Lancaster, M. A. et al. Cerebral organoids model human brain development and microcephaly. Nature 501, 373–379 (2013).
James, O. G. et al. iPSC-derived myelinoids to study myelin biology of humans. Dev. Cell 56, 1346–1358 (2021).
Pereira, J. D. et al. Human sensorimotor organoids derived from healthy and amyotrophic lateral sclerosis stem cells form neuromuscular junctions. Nat. Commun. 12, 4744 (2021).
Van Lent, J. et al. Downregulation of PMP22 ameliorates myelin defects in iPSC-derived human organoid cultures of CMT1A. Brain 146, 2885–2896 (2023).
Faustino Martins, J. M. et al. Self-organizing 3D human trunk neuromuscular organoids. Cell Stem Cell 26, 172–186 (2020).
Rockel, A. F., Wagner, N., Spenger, P., Ergün, S. & Wörsdörfer, P. Neuro-mesodermal assembloids recapitulate aspects of peripheral nervous system development in vitro. Stem Cell Rep. 18, 1155–1165 (2023).
Lischka, A. et al. Genetic pain loss disorders. Nat. Rev. Dis. Prim. 8, 41 (2022).
Rousi, E. et al. An innervated skin 3D in vitro model for dermatological research. Vitr. Models 2, 113–121 (2022).
Muller, Q. et al. Development of an innervated tissue-engineered skin with human sensory neurons and Schwann cells differentiated from iPS cells. Acta Biomater. 82, 93–101 (2018).
Juneja, M. et al. PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease. J. Neurol. Neurosurg. Psychiatry 89, 870–878 (2018).
Jennings, M. J. et al. NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice. Brain 145, 3999–4015 (2022).
Martínez-Muriana, A. et al. CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves. Sci. Rep. 6, 25663 (2016).
Chiu, I. M. et al. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc. Natl Acad. Sci. USA 106, 20960–20965 (2009).
Klein, D. et al. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot–Marie–Tooth disease in mice. Brain 138, 3193–3205 (2015).
Klein, D. et al. Early targeting of endoneurial macrophages alleviates the neuropathy and affects abnormal Schwann cell differentiation in a mouse model of Charcot‐Marie‐Tooth 1A. Glia 70, 1100–1116 (2022).
Gomez-Sanchez, J. A. et al. Schwann cell autophagy, myelinophagy, initiates myelin clearance from injured nerves. J. Cell Biol. 210, 153–168 (2015).
Park, H. T., Kim, J. K. & Tricaud, N. The conceptual introduction of the “demyelinating Schwann cell” in peripheral demyelinating neuropathies. Glia 67, 571–581 (2019).
Jang, S. Y. et al. Schwann cell dedifferentiation-associated demyelination leads to exocytotic myelin clearance in inflammatory segmental demyelination. Glia 65, 1848–1862 (2017).
Weiß, E. M., Geldermann, M., Martini, R. & Klein, D. Macrophages influence Schwann cell myelin autophagy after nerve injury and in a model of Charcot‐Marie‐Tooth disease. J. Peripher. Nerv. Syst. 28, 341–350 (2023).
Vital, A., Vital, C., Julien, J. & Fontan, D. Occurrence of active demyelinating lesions in children with hereditary motor and sensory neuropathy (HMSN) type I. Acta Neuropathol. 84, 433–436 (1992).
Martini, R. & Toyka, K. V. Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patients. Lancet Neurol. 3, 457–465 (2004).
Ginsberg, L. Coexistent hereditary and inflammatory neuropathy. Brain 127, 193–202 (2004).
Malandrini, A., Villanova, M., Dotti, M. T. & Federico, A. Acute inflammatory neuropathy in Charcot-Marie-Tooth disease. Neurology 52, 859–861 (1999).
Fernandez-Lizarbe, S. et al. Neuroinflammation in the pathogenesis of axonal Charcot-Marie-Tooth disease caused by lack of GDAP1. Exp. Neurol. 320, 113004 (2019).
León, M. et al. Rapid degeneration of iPSC-derived motor neurons lacking Gdap1 engages a mitochondrial-sustained innate immune response. Cell Death Discov. 9, 217 (2023).
Yu, C.-H. et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell 183, 636–649 (2020).
Kim, J., Kim, H.-S. & Chung, J. H. Molecular mechanisms of mitochondrial DNA release and activation of the cGAS-STING pathway. Exp. Mol. Med. 55, 510–519 (2023).
Vatine, G. D. et al. Human iPSC-derived blood-brain barrier chips enable disease modeling and personalized medicine applications. Cell Stem Cell 24, 995–1005 (2019).
Kilpinen, H. et al. Common genetic variation drives molecular heterogeneity in human iPSCs. Nature 546, 686 (2017).
Pantazis, C. B. et al. A reference human induced pluripotent stem cell line for large-scale collaborative studies. Cell Stem Cell 29, 1685–1702 (2022).
Boczonadi, V. et al. Mutations in glycyl-tRNA synthetase impair mitochondrial metabolism in neurons. Hum. Mol. Genet. 27, 2187–2204 (2018).
Franco, A. et al. Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A. Elife 9, e61119 (2020).
Wainger, B. J. et al. Modeling pain in vitro using nociceptor neurons reprogrammed from fibroblasts. Nat. Neurosci. 18, 17–24 (2015).
Sanen, K. et al. Engineered neural tissue with Schwann cell differentiated human dental pulp stem cells: potential for peripheral nerve repair? J. Tissue Eng. Regen. Med. 11, 3362–3372 (2017).
Martens, W. et al. Human dental pulp stem cells can differentiate into Schwann cells and promote and guide neurite outgrowth in an aligned tissue‐engineered collagen construct in vitro. FASEB J. 28, 1634–1643 (2014).
Wadman, M. FDA no longer has to require animal testing for new drugs. Science 379, 127–128 (2023).
Imamura, K. et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med 9, eaaf3962 (2017).
Osaki, T., Uzel, S. & Kamm, R. D. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Sci. Adv. 4, 5847 (2018).
Imamura, K. et al. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial. EClinicalMedicine 53, 101707 (2022).
Morimoto, S. et al. Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell 30, 766–780 (2023).
Rocha, A. G. et al. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2. Science 360, 336–341 (2018).
Varkuti, B. H. et al. Neuron-based high-content assay and screen for CNS active mitotherapeutics. Sci. Adv. 6, 8702 (2020).
Shlevkov, E. et al. A high-content screen identifies TPP1 and Aurora B as regulators of axonal mitochondrial transport. Cell Rep. 28, 3224–3237 (2019).
Kim, J.-Y. et al. HDAC6 inhibitors rescued the defective axonal mitochondrial movement in motor neurons derived from the induced pluripotent stem cells of peripheral neuropathy patients with HSPB1 mutation. Stem Cells Int. 2016, 1–14 (2016).
Chumakov, I. et al. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J. Rare Dis. 9, 201 (2014).
Prukop, T. et al. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PLoS ONE 14, 0209752 (2019).
Thenmozhi, R., Lee, J.-S., Park, N. Y., Choi, B.-O. & Hong, Y. B. Gene therapy options as new treatment for inherited peripheral neuropathy. Exp. Neurobiol. 29, 177–188 (2020).
Mercuri, E. et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625–635 (2018).
Rizzo, F. et al. Combined RNA interference and gene replacement therapy targeting MFN2 for the treatment of Charcot-Marie-Tooth type 2 A. Cell Mol Life Sci. 80, 373 (2023).
Bouhy, D. et al. A knock-in/knock-out mouse model of HSPB8-associated distal hereditary motor neuropathy and myopathy reveals toxic gain-of-function of mutant Hspb8. Acta Neuropathol. 135, 131–148 (2018).
Kammoun, M. et al. The invalidation of HspB1 gene in mouse alters the ultrastructural phenotype of muscles. PLoS ONE 11, e0158644 (2016).
Huang, L., Min, J.-N., Masters, S., Mivechi, N. F. & Moskophidis, D. Insights into function and regulation of small heat shock protein 25 (HSPB1) in a mouse model with targeted gene disruption. Genesis 45, 487–501 (2007).
Baylot, V. et al. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol. Ther. 20, 2244–2256 (2012).
Tuma, J. et al. Lipid nanoparticles deliver mRNA to the brain after an intracerebral injection. Biochemistry 62, 3533–3547 (2023).
Stahl, E. C. et al. Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs. Mol. Ther. 31, 2422–2438 (2023).
Hu, B.Y. & Zhang, S.C. Differentiation of spinal motor neurons from pluripotent human stem cells. Nat Protoc. 4, 1295–1304 (2009).
Reinhardt, P. et al. Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling. PLoS One. 8, e59252 (2013).
Amoroso, M.W. et al. Accelerated high-yield generation of limb-innervating motor neuronsfrom human stem cells. J Neurosci. 33, 574–586 (2013).
Fernandopulle, M.S. et al. Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons. Curr Protoc Cell Biol. 79, e51 (2018).
Shi, L. et al. Modeling the Pathogenesis of Charcot-Marie-Tooth Disease Type 1A Using Patient-Specific iPSCs. Stem Cell Reports. 10, 120–133 (2018).
Kitani-Morii, F. et al. Analysis of neural crest cells from Charcot-Marie-Tooth disease patients demonstrates disease-relevant molecular signature. Neuroreport 28, 814–821 (2017).
Sainio, M.T. et al. Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy. Neurol Genet 4, e244 (2018).
Sainio, M.T. et al. Neurofilament Light Regulates Axon Caliber, Synaptic Activity, and Organelle Trafficking in Cultured Human Motor Neurons. Front Cell Dev Biol 9, 820105 (2022).
Rizzo, F. et al. Selective mitochondrial depletion, apoptosis resistance, and increased mitophagy in human Charcot-Marie-Tooth 2A motor neurons. Hum Mol Genet 25, 4266–4281 (2016).
Smith, A.S.T. et al. HDAC6 Inhibition Corrects Electrophysiological and Axonal Transport Deficits in a Human Stem Cell-Based Model of Charcot-Marie-Tooth Disease (Type 2D). Adv Biol 6, e2101308 (2021).
Wolf, C. et al. GDAP1 loss of function inhibits the mitochondrial pyruvate dehydrogenase complex by altering the actin cytoskeleton. Commun Biol 5, 541 (2022).
Lee, G. et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol. 30, 1244–1248 (2012).
Zeltner, N. et al. Capturing the biology of disease severity in a PSC-based model of familial dysautonomia. Nat Med 22, 1421–1427 (2016).
Ajiro, M. et al. Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia. Nat Commun. 12, 4507 (2021).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s12276-024-01250-x